Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer

Cancer Research

Volumn 71, Issue 8, 2011, Pages 3110-3120

  Chang, Qing ^a   Jurisica, Igor ^a,b   Do, Trevor ^a   Hedley, David W ^a,b,c  

^a Campbell Family Institute for Cancer Research   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYTOKERATIN 19; MESSENGER RNA; UVOMORULIN; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; GROWTH RATE; HUMAN; HUMAN TISSUE; HYPOXIA; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PANCREAS CANCER; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BROMODEOXYURIDINE; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; CELL HYPOXIA; DNA, NEOPLASM; GENE EXPRESSION PROFILING; GENES, P53; GENES, RAS; HUMANS; MICE; MICE, SCID; MICROVESSELS; MUTATION; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS;

EID: 79954582454     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-4049     Document Type: Article

References (50)

1. Vaupel P, Mayer A. Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26:225-39. (Pubitemid 47101660)
2. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-9. (Pubitemid 27318643)
3. Brown JM. Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 2002;1:453-8.
4. Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002;20:680-7. (Pubitemid 34111374)
5. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-15. (Pubitemid 26330463)
6. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941-3. (Pubitemid 26065381)
7. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91. (Pubitemid 26008141)
8. Harris AL. Hypoxia- A key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47. (Pubitemid 37328806)
9. Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008;8:851-64.
10. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114-7.
11. Lunt SJ, Chaudary N, Hill RP. The tumor microenvironment and metastatic disease. Clin Exp Metastasis 2009;26:19-34.
12. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 2008;10:295-305.
13. Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev 2007;26:319-31. (Pubitemid 47101665)
14. Lester RD, Jo M, Montel V, , Gonias SL. uPAR induces epithelial- mesenchymal transition in hypoxic breast cancer cells. J Cell Biol 2007;178:425-36. (Pubitemid 47196151)
15. Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci U S A 2008;105:6392-7. (Pubitemid 351758356)
16. Klymkowsky MW, Savagner P. Epithelial-mesenchymal transition: A cancer researcher's conceptual friend and foe. Am J Pathol 2009;174:1588-93.
17. Cannito S, Novo E, Compagnone A, Valfrè di Bonzo L, Busletta C, Zamara E, et al. Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis 2008;29:2267-78.
18. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1:313-23. (Pubitemid 47355323)
19. Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, Murter C, et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 2010;102: 340-51.
20. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009;8:3274-84.
21. Matsumoto K, Arao T, Tanaka K, Kaneda H, Kudo K, Fujita Y, et al. mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res 2009;69: 7160-4.
22. Hill RP, Marie-Egyptienne DT, Hedley DW. Cancer stem cells, hypoxia and metastasis. Semin Radiat Oncol 2009;19:106-11.
23. Hiraoka N, Ino Y, Sekine S, Tsuda H, Shimada K, Kosuge T, et al. Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation. Br J Cancer 2010;103: 1057-65.
24. Iakovlev VV, Pintilie M, Morrison A, Fyles AW, Hill RP, Hedley DW. Effect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IX. Lab Invest 2007;87: 1206-17. (Pubitemid 350126705)
25. Koong AC, Mehta VK, Le QT, Fisher GA, Terris DJ, Brown JM, et al. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 2000;48:919-22.
26. Ng SS, Tsao MS, Nicklee T, Hedley DW. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 2001;7:3269-75. (Pubitemid 32963853)
27. Yau CY, Wheeler JJ, Sutton KL, Hedley DW. Inhibition of integrinlinked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res 2005;65: 1497-504.
28. Cao P, Maira SM, Garcia-Echeverria C, Hedley DW. Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br J Cancer 2009;100:1267-76.
29. Chang Q, Chapman MS, Miner JN, Hedley DW. Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts. BMC Cancer 2010;10:515.
30. Koch CJ. Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5. Methods Enzymol 2002;352:3-31. (Pubitemid 41103167)
31. Vukovic V, Haugland HK, Nicklee T, Morrison AJ, Hedley DW. Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Res 2001;61:7394-8. (Pubitemid 32995022)
32. Allalunis-Turner MJ, Siemann DW. Recovery of cell subpopulations from human tumour xenografts following dissociation with different enzymes. Br J Cancer 1986;54:615-22. (Pubitemid 17182690)
33. Koch CJ. Importance of antibody concentration in the assessment of cellular hypoxia by flow cytometry: EF5 and pimonidazole. Radiat Res 2008;169:677-88. (Pubitemid 351793457)
34. Pham NA, Magalhaes JM, Do T, Schwock J, Dhani N, Cao PJ, et al. Activation of Src and Src-associated signaling pathways in relation to hypoxia in human cancer xenograft models. Int J Cancer 2009;124: 280-6.
35. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RTPCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034.
36. Brown KR, Jurisica I. Unequal evolutionary conservation of human protein interactions in interologous networks. Genome Biol 2007; 8:R95.
37. Brown KR, Otasek D, Ali M, McGuffin MJ, Xie W, Devani B, et al. NAViGaTOR: Network Analysis, Visualization and Graphing Toronto. Bioinformatics 2009;25:3327-9.
38. Kavanagh MC, Tsang V, Chow S, Koch C, Hedley D, Minkin S, et al. A comparison in individual murine tumors of techniques for measuring oxygen levels. Int J Radiat Oncol Biol Phys 1999;44: 1137-46. (Pubitemid 29342916)
39. Chang Q, Chen E, Hedley DW. Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models. Cancer Biol Ther 2009;8:1893-901.
40. Harikumar KB, Kunnumakkara AB, Sethi G, Diagaradjane P, Anand P, Pandey MK, et al. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer 127;257-68.
41. Gortenuti G, Cavallini G, Vantini I, Angelini G, Piubello W, Frasson F, et al. Angiography in chronic pancreatitis and pancreatic cancer. A critical evaluation. Am J Gastroenterol 1978;70:620-6. (Pubitemid 9125737)
42. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394:485-90. (Pubitemid 28373960)
43. Evans SM, Hahn SM, Magarelli DP, Koch CJ. Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. Am J Clin Oncol 2001;24:467-72. (Pubitemid 32959104)
44. Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabè RR, et al. International network of cancer genome projects. Nature 2010; 464:993-8.
45. Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, Mackenzie R, et al. Prognostic factors in resected pancreatic adenocarcinoma: Analysis of actual 5-year survivors. J Am Coll Surg 2004;198: 722-31. (Pubitemid 38542900)
46. Azuma Y, Chou SC, Lininger RA, Murphy BJ, Varia MA, Raleigh JA. Hypoxia and differentiation in squamous cell carcinomas of the uterine cervix: Pimonidazole and involucrin. Clin Cancer Res 2003;9:4944-52. (Pubitemid 37323301)
47. Nordsmark M, Loncaster J, Aquino-Parsons C, Chou SC, Gebski V, West C, et al. The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: A prospective international multi-center study. Radiother Oncol 2006;80:123-31. (Pubitemid 44314011)
48. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007;297:267-77. (Pubitemid 46143304)
49. Tredan O, Garbens AB, Lalani AS, Tannock IF. The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Cancer Res 2009;69:940-7.
50. Marcu L, Olver I. Tirapazamine: From bench to clinical trials. Curr Clin Pharmacol 2006;1:71-9.